These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39059382)

  • 1. Structural basis for the inhibition of βFXIIa by garadacimab.
    Drulyte I; Ghai R; Ow SY; Kapp EA; Quek AJ; Panousis C; Wilson MJ; Nash AD; Pelzing M
    Structure; 2024 Oct; 32(10):1705-1710.e3. PubMed ID: 39059382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of the recombinant β-factor XIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics.
    Pathak M; Manna R; Li C; Kaira BG; Hamad BK; Belviso BD; Bonturi CR; Dreveny I; Fischer PM; Dekker LV; Oliva MLV; Emsley J
    Acta Crystallogr D Struct Biol; 2019 Jun; 75(Pt 6):578-591. PubMed ID: 31205020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure.
    Ow SY; Kapp EA; Tomasetig V; Zalewski A; Simmonds J; Panousis C; Wilson MJ; Nash AD; Pelzing M
    MAbs; 2023; 15(1):2163459. PubMed ID: 36628468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.
    Schoenfeld AK; Lahrsen E; Alban S
    PLoS One; 2016; 11(10):e0165493. PubMed ID: 27783665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting factor XIIa for therapeutic interference with hereditary angioedema.
    Cohn DM; Renné T
    J Intern Med; 2024 Oct; 296(4):311-326. PubMed ID: 39331688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
    McKenzie A; Roberts A; Malandkar S; Feuersenger H; Panousis C; Pawaskar D
    Clin Transl Sci; 2022 Mar; 15(3):626-637. PubMed ID: 34859955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor.
    Esnouf MP; Burgess AI; Dodds AW; Sarphie AF; Miller GJ
    Thromb Haemost; 2000 Jun; 83(6):874-81. PubMed ID: 10896241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
    Pawaskar D; Chen X; Glassman F; May F; Roberts A; Biondo M; McKenzie A; Nolte MW; Jusko WJ; Tortorici M
    Clin Transl Sci; 2022 Mar; 15(3):709-720. PubMed ID: 34811931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the canonical blockade of activated Hageman factor (FXIIa) by benzamidine in the coagulation cascade: A thorough dynamical perspective.
    Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
    Chem Biol Drug Des; 2019 Sep; 94(5):1905-1918. PubMed ID: 31148409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
    Ivanov I; Matafonov A; Sun MF; Mohammed BM; Cheng Q; Dickeson SK; Kundu S; Verhamme IM; Gruber A; McCrae K; Gailani D
    Blood; 2019 Mar; 133(10):1152-1163. PubMed ID: 30591525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients.
    Kajdácsi E; Jandrasics Z; Veszeli N; Makó V; Koncz A; Gulyás D; Köhalmi KV; Temesszentandrási G; Cervenak L; Gál P; Dobó J; de Maat S; Maas C; Farkas H; Varga L
    Front Immunol; 2020; 11():794. PubMed ID: 32431708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contact activation-induced complex formation between complement factor H and coagulation factor XIIa.
    Thangaraj SS; Christiansen SH; Graversen JH; Sidelmann JJ; Hansen SWK; Bygum A; Gram JB; Palarasah Y
    J Thromb Haemost; 2020 Apr; 18(4):876-884. PubMed ID: 31984663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
    Zeerleder S; Levi M
    Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Basis for Bordetella pertussis Interference with Complement, Coagulation, Fibrinolytic, and Contact Activation Systems: the Cryo-EM Structure of the Vag8-C1 Inhibitor Complex.
    Dhillon A; Deme JC; Furlong E; Roem D; Jongerius I; Johnson S; Lea SM
    mBio; 2021 Mar; 12(2):. PubMed ID: 33758081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ongoing contact activation in patients with hereditary angioedema.
    Konings J; Cugno M; Suffritti C; Ten Cate H; Cicardi M; Govers-Riemslag JW
    PLoS One; 2013; 8(8):e74043. PubMed ID: 24013493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19.
    Papi A; Stapleton RD; Shore PM; Bica MA; Chen Y; Larbig M; Welte T
    Lung; 2023 Apr; 201(2):159-170. PubMed ID: 37000214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
    Reshef A; Hsu C; Katelaris CH; Li PH; Magerl M; Yamagami K; Guilarte M; Keith PK; Bernstein JA; Lawo JP; Shetty H; Pollen M; Wieman L; Craig TJ;
    Allergy; 2024 Oct; ():. PubMed ID: 39370961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
    Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S
    Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.